Singapore Patent Expands Island's ISLA 101 Viral Protection
Open PDF
| Stock | Island Pharmaceuticals Ltd (ILA.ASX) |
|---|---|
| Release Time | 2 Jul 2026, 9:38 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Island Pharmaceuticals Ltd Gains Singapore Patent for ISLA 101
Key Points
- Singapore patent for ISLA 101 covers treatment of flavivirus and Chikungunya
- Patent strengthens Island's intellectual property portfolio
- Patent extends until 2034, enhancing commercial opportunities
Full Summary
Island Pharmaceuticals Ltd announced that the Intellectual Property Office of Singapore has granted a patent for the use of ISLA 101 to treat flavivirus, including Dengue, and Chikungunya virus infections. The patent, titled 'Method of Viral Inhibition', covers the use of ISLA 101 as a standalone antiviral therapy and extends until 16 April 2034. This patent strengthens Island's intellectual property portfolio, enhancing its commercial and partnering position in the Asia-Pacific region, where Dengue and other mosquito-borne viral diseases remain endemic.
Outlook
The patent grant further reinforces Island's commercial and partnering position as it advances ISLA-101 for Dengue and other flavivirus indications.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In